Safety, efficacy of dupilumab in atopic dermatitis

Researchers have found that dupilumab may be safe and effective in patients with atopic dermatitis, according to a study published in JAMA Dermatology.

In the study, the researchers assigned 2,677 patients with moderate to severe atopic dermatitis to receive 200 mg of dupilumab once per week. After a follow-up of five years, they found that the medication was well tolerated — showing no new safety issues — and demonstrated sustained efficacy in improving atopic dermatitis symptoms, severity and quality of life. A majority of the patients involved in the study showed clear or almost clear skin by the end of the study period.

The researchers emphasized that the findings supported the long-term use of dupilumab as a treatment option in this patient population.

Read more: JAMA Dermatology

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.